Brice Mouttet, MD, PhD

Brice Mouttet holds a MD-PhD in the field of Very-High-Risk Leukaemia from the Children’s University Hospital Zurich, focussing on proteomic and epigenetic approaches to identify novel treatment approaches for currently “undruggable” oncogenic transcription factors.

He currently works in Sobi’s Business Development team. Prior to joining Sobi, he worked at McKinsey & Company and Novartis.